Literature DB >> 2572258

Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris.

.   

Abstract

Xamoterol has been shown in large, double-blind studies to produce benefit in patients with heart failure. Ischaemic heart disease is the commonest cause of heart failure in the Western World and many patients with heart failure also have angina pectoris (Califf et al., 1982). In view of the known anti-ischaemic effects of xamoterol, we analysed the results of a subgroup of 269 patients with heart failure but without chest pain as a limiting factor on exercise to compare the efficacy of xamoterol in such patients with that of the total group. There were no differences in exercise heart rate, exercise tolerance and symptoms in patients without chest pain compared with the total group. Xamoterol is probably, therefore, acting through myocardial mechanisms other than an anti-ischaemic effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572258      PMCID: PMC1379879     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.

Authors:  L Barrios; J Geboers; J H Piessens; H de Geest
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Antianginal effects of corwin, a new beta-adrenoceptor partial agonist.

Authors:  J M Detry; P M Decoster; J J Buy; M F Rousseau; L A Brasseur
Journal:  Am J Cardiol       Date:  1984-02-01       Impact factor: 2.778

3.  Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man.

Authors:  S Sasayama; S Yokawa; M Akiyama; M Mikawa; O Sakai
Journal:  Jpn Circ J       Date:  1986-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.